When he stepped down as CEO in 2016, Novo cited as reasons increased competition in the U.S. market and pricing pressures for insulin, then its most profitable line. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisks-ceo-shake-up-former-chief-lars-rebien-sorensen-returns-to-influence-leadership-transition/121348649